Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Rapid Readout: Routine Clinical Practice Use of IRd in Patients With Relapsed/Refractory Multiple Myeloma (The INSURE Study)

February 24th 2022

Expert perspective on the INSURE study, which pooled data from several trials to observe the real-world effectiveness of IRd in the setting of relapsed/refractory multiple myeloma.

Dr. Martin on the Patient Population of the CARTITUDE-1 Study in R/R Multiple Myeloma

February 23rd 2022

Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to CT103A for Relapsed/Refractory Myeloma

February 21st 2022

The FDA has granted an orphan drug designation to the investigational anti-BCMA CAR T-cell therapy CT103A for use as a potential therapeutic option in patients relapsed/refractory multiple myeloma.

Ongoing Trials of Belantamab Mafodotin in MM and Optimal Position in Treatment Landscape

February 18th 2022

Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.

Managing AEs With Belantamab Mafodotin in Relapsed/Refractory Myeloma

February 18th 2022

Katja Weisel, MD, shares recommended strategies for the prevention and management of potential ocular effects of belantamab mafodotin in multiple myeloma.

Depth of Response Is a Primary Goal Through Multiple Myeloma Management

February 16th 2022

Cristina Gasparetto, MD, shares pearls regarding treatment in frontline, early relapsed, and late relapsed multiple myeloma.

UCSF Showcases Potentially Game-Changing Trials Across Multiple Myeloma Settings

February 14th 2022

Thomas G. Martin, MD, discusses some of the exciting clinical trials open at UCSF Helen Diller Family Comprehensive Cancer Center in multiple myeloma, especially for those in the relapsed/refractory setting.

Modakafusp Alfa Elicits Single-Agent Activity, Represents a Novel Option in Relapsed/Refractory Myeloma

February 12th 2022

Dan Vogl, MD, MSCE, discusses the unique mechanism of action of modakafusp alfa and the updated results from an expansion cohort in patients with relapsed/refractory multiple myeloma.

Nuanced Decision-Making Strategies Are Needed as the Multiple Myeloma Paradigm Grows

February 11th 2022

Saad Z. Usmani, MD, MBA, FACP, shares key takeaways from presentations given during the meeting on the evolving paradigms of frontline, early relapsed, and late relapsed multiple myeloma, the current role of bispecific antibodies and CAR T-cell therapy, and emerging immunotherapies and also trials in progress in the space.

Updates From ASH 2021 for Belantamab-based Combinations in Myeloma

February 11th 2022

Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.

Role of Belantamab Mafodotin in R/R MM

February 11th 2022

Sagar Lonial, MD, reviews key takeaways from the DREAMM-2 trial, and Katja Weisel, MD, comments on the potential use of belantamab mafodotin in the early relapse setting for multiple myeloma.

Expanded Combinations, Novel Agents, and MRD-Informed Trials Transform Myeloma Paradigm

February 11th 2022

Laura Finn, MD, provides a deep dive into pivotal data with combinations and novel agents that have changed the paradigm for patients with newly diagnosed, early relapsed, and late relapsed multiple myeloma.

Multiple Myeloma Landscape Grows At Rapid Pace With Quadruplets and BCMA-Directed Therapy

February 10th 2022

Douglas W. Sborov, MD, MS, discusses key data and therapeutic developments that have reshaped the treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.

REGN5458 Shows Promising ORR and Safety in Relapsed/Refractory Myeloma

February 9th 2022

Jeffrey Zonder, MD, discusses his presentation at the 2021 ASH Annual Meeting on the impact of the phase 1/2 study utilizing REGN5458 in multiple myeloma.

Risk- and Response-Adaptive Strategies Illuminate New Directions for Multiple Myeloma

February 9th 2022

Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.

Teclistamab/Daratumumab Combo Elicits Encouraging Responses in Relapsed/Refractory Myeloma

February 7th 2022

The subcutaneous combination of the BCMA-targeting bispecific antibody teclistamab and daratumumab produced promising preliminary efficacy and favorable tolerability in heavily pretreated patients with relapsed or refractory multiple myeloma, according to results from the phase 1b TRIMM-2 trial.

Dr. Korde on Updated Findings From the Cassiopeia Trial in Multiple Myeloma

February 4th 2022

Neha S. Korde, MD, hematologist, Memorial Sloan Kettering Cancer Center, discusses key updates to the ​phase 3 Cassiopeia study (NCT02541383) in multiple myeloma.

Clinical Case 2: 59-Year-Old Woman With R/R MM

February 4th 2022

Experts in hematology-oncology review the case of a 59-year-old woman with relapsed/refractory multiple myeloma and discuss their thoughts on the given treatment approach.

Selecting the Appropriate Treatment Regimen and Assessing Response at First Relapse in Myeloma

February 4th 2022

Sagar Lonial, MD; Joshua Richter, MD; and Ola Landgren, MD, PhD, comment on the selection of the appropriate treatment regimen at first relapse, including CD38-based, non-CD38–based and non-PI–based treatment regimens for multiple myeloma, and discuss their approach to assessing treatment response.

ASH 2021: Key Takeaways for Clinical Practice in Multiple Myeloma

February 4th 2022

Closing out his discussion on the ASH 2021 meeting, Saad Usmani, MD, shares key takeaways for clinical practice in multiple myeloma.